SM
PTCT icon

Sabby Management’s PTC Therapeutics PTCT Stock Holding History

Sabby Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,475
Closed -$84K – 175
2018
Q1 		$84K Buy
+1,475
New +$37.4K 0.01% 137
2017
Q4 		– Sell
-1,277
Closed -$2.56M – 182
2017
Q3 		$2.56M Buy
1,277
+300
+31% +$5.87K 0.17% 51
2017
Q2 		$1.79M Buy
977
+824
+539% +$11.1K 0.12% 74
2017
Q1 		$151K Sell
153
-5,787
-97% -$70K 0.01% 227
2016
Q4 		$6.48M Buy
5,940
+1,951
+49% +$20.5K 0.38% 44
2016
Q3 		$5.59M Buy
3,989
+2,249
+129% +$18.3K 0.21% 71
2016
Q2 		$1.22M Buy
1,740
+740
+74% +$5.43K 0.06% 143
2016
Q1 		$644K Buy
1,000
+155
+18% +$2.69K 0.03% 192
2015
Q4 		$2.74M Sell
845
-316
-27% -$9.3K 0.15% 100
2015
Q3 		$3.1M Buy
1,161
+550
+90% +$23.5K 0.13% 123
2015
Q2 		$2.94M Buy
611
+311
+104% +$18.1K 0.11% 130
2015
Q1 		$1.83M Buy
+300
New +$18.3K 0.08% 155

Other funds holding PTCT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Sabby Management's PTCT Position: Q2 2017 in Review

Sabby Management sold out of PTC Therapeutics (PTCT) in Q2 2017, closing a stake of 54,736 shares — an estimated $737K sold.

Sabby Management first reported a position in PTCT in Q3 2015 and held it in 2 quarters. The position peaked at $624K in Q3 2015. 114 funds tracked by Wall St. Rank hold PTCT as of Q2 2017.

  • Sabby Management reported no remaining PTC Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Sabby Management sold 54,736 PTC Therapeutics shares in Q2 2017, an estimated $737K.
  • Sabby Management first reported a position in PTC Therapeutics in Q3 2015 and held it in 2 quarters.
  • Sabby Management's PTC Therapeutics position peaked at $624K in Q3 2015.
  • 114 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.